(a) All patients receiving psychoactive medication will receive timely ongoing face-to-face evaluation and documentation by the prescribing professional of:      
        (1) data collected since the last follow-up, including data about the frequency, severity, and timing of target signs and symptoms;       
        (2) effectiveness of the medication in treating target signs and symptoms; and       
        (3) assessment for side effects and adverse effects.       
      (b) Using the assessment data and with input from the team, the prescribing professional will continue or alter the medication regimen to maximize the benefit to the patient.     
      (c) At initiation of a new medication or significant change  in medication regimen, medication monitoring will occur as often as medically necessary and for the period of time needed to stabilize the clinical response. Such monitoring will occur at least weekly for one month in hospitals and crisis stabilization units (unless discharged in the interim) and at least monthly in outpatient and residential settings. Rationale for less frequent monitoring will be documented.     
      (d) Further minimum frequencies of medication monitoring in patients are:      
        (1) state mental health facility settings--monthly as described in subsections (a) and (b) of this section. Also, every 90 days, the medication monitoring includes review of consent issues and long-term consequences of psychoactive medication;       
        (2) state mental retardation facility settings--monthly review of data with appropriate members of the team and every third month (quarterly) face-to-face evaluation of the patient. Rationale for less frequent monitoring will be documented;       
        (3) LA programs--medication monitoring appointments will be scheduled quarterly as described in subsections (a) and (b) of this section. Rationale for less frequent monitoring will be documented.       
      (e) For medications known to cause movement disorders, appropriately trained and competent staff will screen the patient quarterly for abnormal involuntary movements using a standardized procedure such as AIMS, document the results, and arrange for any appropriate follow-up with a psychiatrist or  neurologist, if indicated.     
      (f) Clinically significant adverse effects or side effects will be evaluated by a physician, managed according to accepted guidelines, and addressed in the plan of care.     
      (g) Laboratory testing or other procedures needed for the continued safe and effective use of medication will be ordered according to accepted guidelines.     
      (h) In any service setting that operates a pharmacy, the pharmacist will evaluate medication orders and patient medication records in accordance with the rules of the Texas State Board of Pharmacy (Texas Administrative Code, Title 22, Part 15) and will include a review for dosage range according to the TDMHMR Formulary, polypharmacy, and PRN use. The service setting will  have policies and procedures in place for doing this review and the documentation and outcome of any questions arising out of this review.     
     Source Note:        The provisions of this §5.10 adopted to be effective August 31, 2004, 29 TexReg 8325; transferred effective September 1, 2004, as published in the Texas Register September 10, 2004, 29 TexReg 8841